Investigational Vaccine Designed to Provide Broad, Durable Protection from Flu
The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in healthy volunteers. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, developed the experimental vaccine, known as H1ssF_3928.
Credit: National Institute of Allergy and Infectious Diseases (NIAID)
The post NIH Begins First-in-Human Trial of a Universal Influenza Vaccine Candidate appeared first on Healthier Environment Living Program.